```markdown

---

title: "Illumina Wins FDA Breakthrough Device Designation for Pan-Cancer cfDNA Assay"

date: 2026-06-24

category: Product

excerpt: "Illumina's TruSight Oncology Liquid 500 assay receives FDA Breakthrough Device Designation, accelerating its path to clinical market."

sponsored: false

---

Illumina announced this week that its TruSight Oncology Liquid 500 assay has received FDA Breakthrough Device Designation, marking a significant regulatory milestone for the company's liquid biopsy portfolio and signaling renewed momentum in the clinical oncology genomics space. The assay, which analyzes circulating cell-free DNA (cfDNA) across more than 500 clinically relevant variants in a single workflow, is designed to support therapy selection and minimal residual disease monitoring across multiple solid tumor types.

Background

The Breakthrough Device Designation program is intended to expedite the development and review of medical devices that provide more effective treatment or diagnosis of life-threatening conditions. For Illumina, the designation represents a meaningful pivot following years of organizational restructuring and the divestiture of GRAIL. The TruSight Oncology Liquid 500 was initially launched in a research-use-only configuration in late 2025, but the company has been pursuing clinical validation data in partnership with several major academic cancer centers, including MD Anderson Cancer Center and Memorial Sloan Kettering, ahead of a formal premarket approval submission expected in the first half of 2027.

The assay leverages Illumina's proprietary DRAGEN bioinformatics pipeline and is designed to operate on the NovaSeq X Series, giving hospital-based laboratories the option to run the test in-house rather than relying on centralized reference laboratories. Industry analysts have noted that the in-house angle could be a competitive differentiator against established players such as Foundation Medicine and Guardant Health, particularly for health systems seeking to reduce turnaround times and per-test costs.

What This Means for the Market

The designation is expected to intensify competition in an already crowded liquid biopsy landscape. Guardant Health's Guardant360 and Foundation Medicine's FoundationOne Liquid CDx both hold FDA approval, giving them a first-mover advantage with payers and oncology practices. However, Breakthrough Device Designation typically shortens FDA review timelines and facilitates more frequent communication between sponsors and the agency, which could allow Illumina to close that gap faster than the market anticipates. Reimbursement remains the central challenge, with Medicare coverage policies for multi-analyte liquid biopsy panels still evolving under the MolDx program.

Looking Ahead

Illumina has indicated it plans to present clinical validation data from its academic partnerships at the European Society for Medical Oncology Congress this September. A successful data readout combined with an accelerated FDA review timeline could position the TruSight Oncology Liquid 500 for commercial launch before the end of 2027, making the next eighteen months pivotal for the company's oncology diagnostics strategy.

```